Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Holdings Cut by Federated Hermes Inc.

Federated Hermes Inc. lessened its position in Century Therapeutics, Inc. (NASDAQ:IPSC) by 55.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 276,163 shares of the company’s stock after selling 338,980 shares during the period. Federated Hermes Inc.’s holdings in Century Therapeutics were worth $704,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Rhumbline Advisers grew its holdings in Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Century Therapeutics by 110.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Century Therapeutics by 191.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock worth $1,229,000 after purchasing an additional 192,915 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Century Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock worth $4,760,000 after purchasing an additional 14,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Century Therapeutics during the first quarter worth approximately $47,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

IPSC has been the topic of several research reports. Piper Sandler upped their price target on Century Therapeutics from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Monday, June 17th. HC Wainwright cut their target price on Century Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Finally, Rodman & Renshaw began coverage on Century Therapeutics in a research report on Thursday, August 8th. They issued a “buy” rating and a $6.00 price target for the company.

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC opened at $1.70 on Monday. The firm has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $2.86. Century Therapeutics, Inc. has a 52 week low of $1.28 and a 52 week high of $5.51. The company has a market cap of $143.65 million, a PE ratio of -0.77 and a beta of 1.36.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.12. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.55 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. On average, equities analysts predict that Century Therapeutics, Inc. will post -1.8 earnings per share for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.